AstraZeneca Liver Cancer Regimen Extends Progression-Free Survival in Phase III Trial

Source Summary

WILMINGTON, DE — AstraZeneca (LSE/STO/NYSE: AZN) reported Phase III trial results showing that a combination of its immunotherapy drugs IMFINZI and IMJUDO with lenvatinib and transarterial chemoembolization (TACE) significantly delayed ...